Lipophilic versus hydrophilic β1 blockers and the cardiac sympatho- vagal balance during stress and daily activity in patients after acute myocardial infarction

Heart

Volumn 79, Issue 2, 1998, Pages 153-160

  Kardos, A ^a   Long, V ^a   Bryant, J ^a   Singh, J ^a   Sleight, P ^a   Casadei, B ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Adrenergic receptors; Baroreceptors; Myocardial infarction; Stress

Indexed keywords

ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL;

ACUTE HEART INFARCTION; ADRENERGIC SYSTEM; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXERCISE TEST; FEMALE; HEART RATE; HUMAN; MALE; OXYGEN CONSUMPTION; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; STRESS;

EID: 0031896341     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.79.2.153     Document Type: Article

References (33)

1. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
2. Conway PG, Tejani-Butt S, Brunswick DJ. Interaction of beta adrenergic agonists and antagonists with brain beta adrenergic receptors in vivo. J Pharmacol Exp Ther 1987;241:755-62.
3. Parker GW, Michael LH, Hartley CJ, et al. Central β-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs. Circ Res 1990;66:259-70.
4. Wikstrand J, Kendall M. The role of beta receptor blockade in preventing sudden death. Eur Heart J 1992;13(suppl D):111-20.
5. Lewis PJ, Haeusler G. Reduction in sympathetic nervous activity as a mechanism for the hypotensive effect of propranolol. Nature 1975;256:440.
6. Coker R, Koziell A, Oliver C, et al. Does the sympathetic nervous system influence sinus arrhythmia in man? Evidence from combined autonomic blockade. J Physiol (Lond) 1984;356:459-64.
7. Cook JR, Bigger JT, Kleiger RE, et al. Effect of atenolol and diltiazem on heart period variability in normal persons. J Am Coll Cardiol 1991;17:480-4.
8. Scott EM. The effects of atenolol on spontaneous and reflex activity of the sympathetic nerves in the anaesthetized cat. Br J Pharmacol 1981;73:609-16.
9. Tuininga YS, Crijns HJGM, Brouwer J, et al. Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients. Circulation 1995;92:3415-23.
10. Schwartz PJ, Zaza A, Pala M, et al. Baroreflex sensitivity and its evolution during the first year after myocardial infarction. J Am Coll Cardiol 1988;12:629-36.
11. Bigger JT, Fleiss JL, Rolnitzky LM, et al. Time course of heart period variability after myocardial infarction. J Am Coll Cardiol 1991;18:1643-9.
12. Bristow JD, Brown EBJ, Cunningham DJC, et al. The effects of hypercapnia, hypoxia and ventilation on the baroreflex regulation of the pulse interval. J Physiol (Lond) 1971;216: 281-302.
13. Dahlöf C, Dimenäs E, Olofsson B. Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacology. Cardiovasc Drug Ther 1989;3:919-27.
14. De Boer RW, Karemaker JM, Strackee J. Comparing spectra of a series of point events, particularly of heart rate variability data. IEEE Trans Biomed Eng 1984;31:384-7.
15. Harris FJ. On the use of windows for harmonic analysis with the discrete Fourier transform. IEEE Trans Biomed Eng 1978;66:51-83.
16. Bigger JT, Fleiss JL, Steinman RC, et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164-71.
17. Rottman JN, Steinman R, Albrecht P, et al. Efficient estimation of the heart period power spectrum suitable for physiologic or pharmacologic studies. Am J Cardiol 1990;66: 1522-4.
18. Ripley KL, Murray A. Introduction to automated arrhythmia detection. New York: IEEE Comp Society Press, 1980.
19. Casadei B, Moon J, Caiazza A, et al. Is respiratory sinus arrhythmia a good index of cardiac vagal activity during exercise? J Appl Physiol 1996;81:556-64.
20. Mathias CJ, Bannister R, Cortelli P, et al. Clinical, autonomic and therapeutic observations in two siblings with postural hypotension and sympathetic failure due to an inability to synthesize noradrenaline from dopamine because of a deficiency of dopamine beta hydroxylase. Q J Med 1990;75:617-33.
21. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979;8:7-20.
22. Blomqvist I, Westergren G, Sandberg A, et al. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol. Eur J Clin Pharmacol 1988;33:S19-24.
23. Dimenäs E, Östergren J, Lindvall K, et al. Comparison of CNS-related subjective symptoms in hypertensive patients treated with either a new controlled release (CR/ZOK) formulation of metoprolol or atenolol. J Clin Pharmacol 1990; 30:S82-90.
24. Cruickshank JM, Neil-Dwyer G, Cameron MM, et al. β-Adrenoreceptor-blocking agents and the blood-brain barrier. Clin Sci 1980;59:453-5s.
25. Julian DG, Prescott RJ, Jackson FS, et al. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;i:1142-50.
26. Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990; 65:74-81A.
27. Niemelä MJ, Airaksinen KEJ, Huikuri HV. Effect of beta-blockade on heart rate variability in patients with coronary artery disease. J Am Coll Cardiol 1994;23:1370-7.
28. Airaksinen KEJ, Niemelä MJ, Huikuri HV. Effect of beta-blockade on baroreflex sensitivity and cardiovascular autonomic function tests in patients with coronary artery disease. Eur Heart J 1994;15:1482-5.
29. Flapan AD, Wright RA, Nolan J, et al. Differing pattern of cardiac parasympathetic activity and their evolution in selected patients with a first myocardial infarction. J Am Coll Cardiol 1993;21:926-31.
30. Elborn JS, Stanford CF, Nicholls DP. Reproducibility of cardiopulmonary parameters during exercise in patients with chronic cardiac failure. The need for a preliminary test. Eur Heart J 1990;11:75-81.
31. Sandberg A, Abrahamsson B, Regårdh C-G, et al. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article. J Clin Pharmacol 1990;30:S2-16.
32. Schroder H. Cytochrome P-450 mediates bioactivation of organic nitrates. J Pharmacol Exp Ther 1992;262:298-302.
33. Pankow D, Damme B, Schror K. Acetylsalicyclic acid inducer of cytochrome P-450 2E1? Arch Toxicol 1994;68: 261-5.